Belatacept as salvage maintenance immunosuppression in a liver transplant recipient
Belatacept is a novel fusion protein that blocks signal two of T cell activation. Belatacept was approved in 2015 for the prevention of acute rejection in kidney transplant recipients. Results from a 2014 phase II clinical trial in liver transplant recipients was terminated early due to an increased...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | Transplantation Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451959620300317 |